These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 9716090)

  • 1. Catechol-O-methyltransferase inhibitors in Parkinson's disease.
    Harper J; Vieira B
    Lancet; 1998 Aug; 352(9127):578. PubMed ID: 9716090
    [No Abstract]   [Full Text] [Related]  

  • 2. Extending levodopa action: COMT inhibition.
    Martínez-Martín P; O'Brien CF
    Neurology; 1998 Jun; 50(6 Suppl 6):S27-32; discussion S44-8. PubMed ID: 9633684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Catechol-O-methyltransferase inhibitors in Parkinson's disease.
    Henry C; Wilson JA
    Lancet; 1998 Jun; 351(9120):1965-6. PubMed ID: 9654299
    [No Abstract]   [Full Text] [Related]  

  • 4. Vitiligo associated with tolcapone and levodopa in a patient with Parkinson's disease.
    Sabaté M; Bosch A; Pedrós C; Figueras A
    Ann Pharmacother; 1999 Nov; 33(11):1228-9. PubMed ID: 10573327
    [No Abstract]   [Full Text] [Related]  

  • 5. Rasagiline for motor complications in Parkinson's disease.
    Clarke CE
    Lancet; 2005 Mar 12-18; 365(9463):914-6. PubMed ID: 15766976
    [No Abstract]   [Full Text] [Related]  

  • 6. Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease.
    Nutt JG
    Lancet; 1998 Apr; 351(9111):1221-2. PubMed ID: 9643737
    [No Abstract]   [Full Text] [Related]  

  • 7. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
    Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G
    Neurology; 1998 May; 50(5 Suppl 5):S46-53. PubMed ID: 9591522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolcapone for Parkinson's disease.
    Med Lett Drugs Ther; 1998 Jun; 40(1028):60-1. PubMed ID: 9629124
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety and tolerability of COMT inhibitors.
    Brooks DJ
    Neurology; 2004 Jan; 62(1 Suppl 1):S39-46. PubMed ID: 14718679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Tolcapone Stable Study Group.
    Waters CH; Kurth M; Bailey P; Shulman LM; LeWitt P; Dorflinger E; Deptula D; Pedder S
    Neurology; 1998 May; 50(5 Suppl 5):S39-45. PubMed ID: 9591521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects.
    Russ H; Müller T; Woitalla D; Rahbar A; Hahn J; Kuhn W
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Dec; 360(6):719-20. PubMed ID: 10619191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, pharmacodynamics, and tolerability of tolcapone: a review of early studies in volunteers.
    Jorga KM
    Neurology; 1998 May; 50(5 Suppl 5):S31-8. PubMed ID: 9591520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
    Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
    Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Catechol-O-methyltransferase inhibitors: new options for Parkinson's disease.
    Leicht MJ; Mitchell SD
    S D J Med; 1999 Aug; 52(8):295-7. PubMed ID: 10453205
    [No Abstract]   [Full Text] [Related]  

  • 15. Neuroleptic malignant-like syndrome in an elderly patient caused by abrupt withdrawal of tolcapone, a-catechol-o-methyl transferase inhibitor.
    Iwuagwu CU; Riley D; Bonoma RA
    Am J Med; 2000 Apr; 108(6):517-8. PubMed ID: 10866587
    [No Abstract]   [Full Text] [Related]  

  • 16. The levodopa wearing-off phenomenon in Parkinson's disease: pharmacokinetic considerations.
    Stocchi F
    Expert Opin Pharmacother; 2006 Jul; 7(10):1399-407. PubMed ID: 16805724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Catechol-O-methyltransferase (COMT) inhibitors in Parkinson's disease.
    Waters C
    J Am Geriatr Soc; 2000 Jun; 48(6):692-8. PubMed ID: 10855610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline.
    Davis TL; Roznoski M; Burns RS
    Mov Disord; 1995 May; 10(3):349-51. PubMed ID: 7651456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial.
    Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P;
    Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients. Tolcapone Study Group.
    Mov Disord; 1999 Jan; 14(1):38-44. PubMed ID: 9918342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.